Denali Therapeutics Inc.NASDAQ: DNLI

Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV: IDS) Treatment in MPS II (Hunter Syndrome)

· Issued by Denali Therapeutics Inc.
  • Interim results demonstrate average reduction of 64% (p

Denali Therapeutics Inc. on 6ix

In the deck

Story so far

Earlier from Denali Therapeutics

Later from Denali Therapeutics

All Denali Therapeutics news releases